-
Greenwich LifeSciences reports progress on FLAMINGO-01 breast cancer trial
-
Greenwich LifeSciences reports 80% recurrence reduction in cancer trial
-
Greenwich LifeSciences completes enrollment in open label arm of phase III trial
-
Greenwich LifeSciences screens over 1,000 patients in phase III trial
-
Greenwich LifeSciences adds Austria to Phase III breast cancer trial
-
Greenwich LifeSciences expands breast cancer trial to Belgium
-
Greenwich LifeSciences expands FLAMINGO-01 trial to Portugal
-
Greenwich LifeSciences expands breast cancer trial to Ireland
-
Noble Capital Starts Greenwich LifeSciences (GLSI) at Outperform
-
Greenwich LifeSciences builds internal clinical operations team
-
Greenwich LifeSciences expands breast cancer trial to Romania
-
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Greenwich LifeSciences (GLSI) PT Raised to $39 at H.C. Wainwright
-
Greenwich LifeSciences (GLSI) Provides Global Update on FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
-
Greenwich LifeSciences (GLSI) Provides Update on Open Label Safety Data from FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Provides Update on Open Label HLA Data from FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Provides Update on Commercial Manufacturing
-
Greenwich LifeSciences (GLSI) Announces Partnership with GBG in Germany for Flamingo-01
-
Greenwich LifeSciences (GLSI) Provides Update on Expansion of Flamingo-01 into Spain
-
Greenwich LifeSciences (GLSI) to Rejoin Russell 2000 Index
-
Greenwich LifeSciences (GLSI) Announces 175K Private Placement at $14.30/sh

